fluad.comFLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for 65+ | CSL Seqirus flu360

Please maximize your window to view this content. For US Healthcare Professionals Only For GB Healthcare Professionals Only Prescribing Information FLUAD ® QUADRIVALENT FLUCELVAX ® QUADRIVALENT AFLURIA ® QUADRIVALENT Important Safety Information FLUAD ® QUADRIVALENT FLUCELVAX ® QUADRIVALENT AFLURIA ® QUADRIVALENT About Support Log In For US Healthcare Professionals Only For GB Healthcare Professionals Only flu360 ® Overview Overview Clinical Support Adjuvant Technology Cell Technology Influenza Burden 65+ Years Influenza Burden Financial Guidance Coding and Billing Operational Efficiency Products All Products FLUAD ® QUADRIVALENT FLUCELVAX ® QUADRIVALENT AFLURIA ® QUADRIVALENT Tools & Resources Create Account flu360 ® Overview Overview Clinical Support Adjuvant Technology Cell Technology Influenza Burden 65+ Years Influenza Burden Financial Guidance Coding and Billing Operational Efficiency Products All Products FLUAD ® QUADRIVALENT FLUCELVAX ® QUADRIVALENT AFLURIA ® QUADRIVALENT Tools & Resources Important Safety Information FLUAD ® QUADRIVALENT FLUCELVAX ® QUADRIVALENT AFLURIA ® QUADRIVALENT Prescribing Information FLUAD ® QUADRIVALENT FLUCELVAX ® QUADRIVALENT AFLURIA ® QUADRIVALENT About Support Create Account Log In × Your session is about to time out. Any in-progress updates won’t be saved. Session timeout in: : Continue Session Log Out You are now being redirected to flu360 If the page does not redirect please click hereFLUAD QUADRIVALENT The Adjuvant Advantage Clinical Data Real-World Evidence Order Now FLUAD ® QUADRIVALENT The Adjuvant Advantage Clinical Data Real-World Evidence Order Now HomeProductsFLUAD QUADRIVALENT challenges of protecting adults 65+ really add up. Weakened Immune Systems Weakened Immune Systems More susceptible to influenza 2,3 Less able to generate a sufficient immune response to standard flu vaccines 2,3 + strain mismatch strain mismatch Can decrease vaccine effectiveness especially in an already vulnerable population 4,5 7 out of 10 recent US flu seasons were impacted by strain mismatch *5-15 More susceptible to influenza 2,3 Less able to generate a sufficient immune response to standard flu vaccines 2,3 Can decrease vaccine effectiveness especially in an already vulnerable population 4,5 7 out of 10 recent US flu seasons were impacted by strain mismatch *5-15 *2010-2011 through 2019-2020 US influenza seasons. FLUAD QUADRIVALENT IS DESIGNED TO ADDRESS THESE CHALLENGES That’s the Adjuvant Advantage. When you choose FLUAD QUADRIVALENT for your older patients, you boost their ability to fight off flu with an adjuvant that strengthens, broadens, and lengthens the immune response. Learn how it does more than antigen alone. 16-19 See the Difference Clinical data backed by over 20 years of real-world evidence FLUAD QUADRIVALENT has clinical trial data demonstrating a robust immune response. 16 The Adjuvant Advantage* is further demonstrated by the findings of RWE in over 59 million adults 65+. 20-32 View Clinical Data Real-World Evidence *Preferentially recommended by ACIP for adults 65+ over non-adjuvanted, standard-dose influenza vaccines. Choose FLUAD QUADRIVALENT for your eligible patients 65+ years 16 Covered by Medicare Part B and by most Medicare Advantage Plans with no copay* CPT reimbursement code Single-dose syringe: 90694 Order Now *This information does not constitute a guarantee or warranty of coverage benefits or reimbursement. MORE FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), FLUCELVAX® QUADRIVALENT (Influenza Vaccine), and AFLURIA® QUADRIVALENT (Influenza Vaccine) FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), FLUCELVAX® QUADRIVALENT (Influenza Vaccine), and AFLURIA® QUADRIVALENT (Influenza Vaccine) INDICATION AND IMPORTANT SAFETY INFORMATION IMPORTANT SAFETY INFORMATION INDICATIONS AND USAGE FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older. This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. FLUCELVAX® QUADRIVALENT (Influenza Vaccine) is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 6 months of age and older. AFLURIA® QUADRIVALENT (Influenza Vaccine) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older. CONTRAINDICATIONS Do not administer FLUAD QUADRIVALENT or AFLURIA QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine. Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine. WARNINGS AND PRECAUTIONS If Guillain-Barré syndrome (GBS) has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give FLUAD QUADRIVALENT, FLUCELVAX QUADRIVALENT, or AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine. Syncope (fainting) may occur in association with administration of injectable vaccines. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Ensure procedures are in place to avoid falling injury and to restore cerebral perfusion following syncope by maintaining a supine or Trendelenburg position. The immune response to FLUAD QUADRIVALENT, FLUCELVAX QUADRIVALENT, or AFLURIA QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals. Vaccination with FLUAD QUADRIVALENT, FLUCELVAX QUADRIVALENT, or AFLURIA QUADRIVALENT may not protect all vaccine recipients against influenza disease. ADVERSE REACTIONS FLUAD QUADRIVALENT: The most common (≥ 10%) local and systemic reactions with FLUAD QUADRIVALENT in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%). Other adverse events may occur. FLUCELVAX QUADRIVALENT: In children 6 months through 3 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (27.9%), erythema (25.8%), induration (17.3%) and ecchymosis (10.7%). The most common systemic adverse reactions were irritability (27.9%), sleepiness (26.9%), diarrhea (17.9%) and change of eating habits (17.4%). In children 2 through 8 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were tenderness (28.7%), pain (27.9%) and erythema (21.3%), induration (14.9%) and ecchymosis (10.0%). The most common systemic adverse reactions were sleepiness (14.9%), headache (13.8%), fatigue (13.8%), irritability (13.8%) and loss of appetite (10.6%). In children and adolescents 9 through 17 years of age who received FLUCELVAX QUADRIVALENT, the most commonly reported injection-site adverse reactions were injection site pain (21.7%), erythema (17.2%) and induration (10.5%). The most common systemic adverse reactions were headache (18.1%) and fatigue (17.0%). In adults 18 through 64 years of age who received FLUCELVAX QUADRIVALENT,...